• Press Release
  • COVID-19
  • Press

WHOOP to Be First 24/7 Wearable Used in COVID-19 Vaccine Trials


WHOOP to Be First 24/7 Wearable Used in COVID-19 Vaccine Trials

G42 Healthcare Partners with WHOOP to Enhance Volunteer Experience in World's First Phase III Trials of Inactivated COVID-19 Vaccine.

Abu Dhabi-based G42 Healthcare is conducting the world’s first Phase III clinical trial of a COVID-19 inactivated vaccine, and has just announced a volunteer healthcare management program in partnership with WHOOP. The trials are expected to include 15,000 volunteers in the UAE who will have the option to wear WHOOP and benefit from 24/7 fitness and health monitoring of key biometrics. This is the first trial of its kind to feature wearable technology.


The Whoop4Humanity initiative ensures that participants who join the clinical trials can further enhance their volunteer experience by using WHOOP to check their daily heart rate, respiratory rate, heart rate variability, sleep performance, and more. Commenting on the new partnership, G42 Healthcare CEO Ashish Koshy said: “As a digital business, this new partnership is a logical extension of the highly-advanced AI and super computer solutions we are already using in the trials process. New volunteers will be invited to engage with the technology developed by WHOOP to enhance their individual volunteer experience and contribute to the advanced research involved in these sophisticated trials.” “We believe that giving volunteers an opportunity to use the WHOOP Strap 3.0 wearable device will reinforce their confidence in the trial by giving them the ability to check on several daily health data points. This will complement the world-class clinical expertise that the healthcare professionals in the UAE are providing to the volunteers and ensure their safety and well-being throughout the trials process.” G42 Healthcare believes that WHOOP can be a powerful tool to boost the comprehensive volunteer healthcare management program by helping thousands of vaccine volunteers to self-monitor their well-being while measuring their fitness, sleep, and recovery levels during the trials. WHOOP provides valuable insights and actionable feedback around specific markers, thus encouraging better decision making for volunteers’ health.


WHOOP uniquely blends hardware, software, and industry-leading accurate measurements to help people sharpen the edges of performance, create impactful behavior change and a new set of positive individual habits, and empower them to optimize all facets of life. Earlier this year, WHOOP made public research on the utility of its wearable technology in providing early warning signs of potential COVID-19 infections, in particular by tracking respiratory rate during sleep. Learn more about WHOOP research with COVID-19 detection and resilience.


The trials began in Abu Dhabi on July 16th and are being managed by G4 Healthcare in partnership with the Department of Health - Abu Dhabi, the UAE Ministry of Health and Prevention (MOHAP) and Abu Dhabi Health Services Company (SEHA). They are being conducted following the international guidelines stipulated by the World Health Organization (WHO) and the United States Food & Drug Administration (USFDA). The Phase III clinical trials follow the success of the Phase I and Phase II trials conducted by Sinopharm in China, which resulted in 100% of the volunteers generating antibodies to SARS-CoV-2, the virus that causes COVID-19, after two doses in 28 days. The Phase III trials are open to individual volunteers aged between 18 and 60 living in the UAE and Bahrain and will last for six to twelve months, with the volunteers required to be available for follow ups during this time. The products and services of WHOOP are not medical devices, are not intended to diagnose COVID-19, the flu or any other disease, and should not be used as a substitute for professional medical advice, diagnosis or treatment. All content available through the products and services of WHOOP is for general informational purposes only.